HeartSciences expands equity plan to 1M shares, grants RSUs and options tied to FDA clearance

HeartSciences Inc.

Board approved amendment to 2023 Equity Incentive Plan increasing maximum shares to 1,000,000; subject to shareholder vote at next annual meeting.
CEO Andrew Simpson received 68,750 RSUs; COO Mark Hilz received 56,250 RSUs; vest upon FDA clearance of MyoVista Device or Change of Control.
Granted options: CEO 275,000, COO 225,000, CFO 25,000 at $4.37/share, vesting over three years with acceleration on FDA clearance.
Non-employee directors each received 25,000 options at $4.37.
As of July 11, 2025, raised $1.7M from Reg A offering (487,701 units) and exchanged $855K debt for 233,229 shares; total shares outstanding ~1.555M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.